Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Date:11/6/2009

----------------------- ----- ----- ----- ----- Mean change in weight (kg) -0.27 -0.28 -1.13 -3.09* ------------------------- ----- ----- ----- ----- *p = < 0.05

Although the treatment duration in the study was only 28 days, decreases in HbA1c and body weight were observed across all dose arms. Changes in HbA1c from baseline were statistically significant across all treatment arms. The most commonly reported adverse events were nausea and vomiting, which were mostly mild, transient, dose dependent and limited to the first week of therapy.

"The results from the phase 1b study demonstrate a pronounced effect on HbA1c and body weight after just 4 weeks of treatment with ITCA 650," said Kenneth L. Luskey, MD, Chief Medical Officer at Intarcia. "ITCA 650 holds the potential to deliver much longer durations of continuous therapy from a single device, and that is currently under clinical investigation."

In addition to its phase 1b clinical data, Intarcia also presented for the first time results of studies demonstrating the ability of DUROS delivery technology to maintain stability of exenatide at human body temperature and to continuously deliver exenatide for as long as 12 months from a single DUROS device. Purity of exenatide was maintained at levels above 99% for all time points at both room temperature and human body temperature, and bioactivity of exenatide was unchanged throughout the 12-month study duration.

"These studies show that ITCA 650 can deliver 6, 9, or 12 months of exenatide from a single DUROS device," said Thomas Alessi, PhD, Vice President, Development and Manufacturing at Intarcia. "DUROS delivery is designed to provide important clinical advantages to patients and physicians by eliminating the need for self-injection, ensuring 100% compliance and improving tolerability and convenience."

Intarcia is currently conduc
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain Resiliency ... and resiliency practitioners with luminaries and thought leaders to advance the professional discipline ... their innovations and performance excellence. At that time its principle sponsor, Resilinc ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $5.7 million. The orders are for air emission abatement projects in ... note is a large order for a municipality in the ... be replacing a competitor,s system that failed to meet the ... engineered solutions," said Derek S. Webb , President and ...
(Date:8/31/2015)... ... August 31, 2015 , ... In recent ... properties such as low carbon footprints and compostability. These properties can help in ... plastics. On the basis of applications, the market for biodegradable plastics can be ...
(Date:8/31/2015)... -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical stage ... antibody, HuMab 5B1, will be garnering major attention as ... World Molecular Imaging Congress (WMIC) being held in ... the Department of Radiology at Memorial Sloan Kettering Cancer ... MabVax,s lead antibody as a PET imaging agent and ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround ... for Core Business ... Agreements, IRVING, Texas, Aug. 14 Carrington,Laboratories, Inc. (Nasdaq: CARN ) reported ... in the year ago,period. The revenue in the quarter just ended, while 17 percent ...
... Summertime equals fun for a lot of,folks. ... (IBS), typical,summer fare could also mean aggravating their ... for IBS," has more on,what people with IBS ... IBS from,ruining their celebrations. Listen to this ...
... Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... and markets advanced in-,vitro diagnostic products and high ... it will participate in the Morgan,Stanley,s 2007 China ... Date: August 21, 2007 China Medical Technologies, ...
Cached Biology Technology:Carrington Reports Second Quarter 2007 Results 2Carrington Reports Second Quarter 2007 Results 3Carrington Reports Second Quarter 2007 Results 4Carrington Reports Second Quarter 2007 Results 5Carrington Reports Second Quarter 2007 Results 6Carrington Reports Second Quarter 2007 Results 7
(Date:8/31/2015)... Growing need for data security ... projects to drive India biometrics market ... report, " India Biometrics Market Forecast & Opportunities, 2020 ", ... to grow at a CAGR of over 35% during 2015 ... of extensive use of biometric technology in the government sector. ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/28/2015)... , August 28, 2015 According ... Training Market by Assessment Type (Pen & Paper Based, ... Training, Corporate Learning, Academic Research), Vertical and Region - ... and Training Market to grow from USD 2.4 Billion ... a Compound Annual Growth Rate (CAGR) of 25.6% from ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... release is available in French . ... and dosage of antipsychotics may influence their efficacy, reported Philippe ... mentale de Montral and Universit de Montral. The efficacy of ... get into the bloodstream after being absorbed. Vincent and Kouassi ...
... healthy and then we weaken and die - that,s probably how ... the phenomenon of ageing shows an unexpected diversity of patterns and ... Denmark. Not all species weaken and become more likely ... likely to die with age, while others are not affected by ...
... The Children,s Hospital of Philadelphia have manipulated key biological ... of hemoglobin normally absent after the newborn period. Because ... in sickle cell disease (SCD), the cell culture findings ... the debilitating blood disorder. "Our study shows ...
Cached Biology News:How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy? 2Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2
Mouse Laminin-1 MAb (Clone AL-3)...
IEX-1 S/L (H-20)...
... reactivity with rat (100%), mouse ... pig (48%). Slight reactivity ... confirmed by Western blot versus ... Gia-1, Gia-2, rat Gia-3, bovine ...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: